Sugi Predict

Sugi Predict / Targets / MAPKAP1

MAPKAP1

Target of rapamycin complex 2 subunit MAPKAP1 · Q9BPZ7 · MAPKAP1 on Sugi Atlas →

11,489 patent compounds predicted against MAPKAP1, 8,815 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL446433 SCHEMBL446433 0.49 10/20
SCHEMBL446434 SCHEMBL446434 0.49 10/20
SCHEMBL443760 SCHEMBL443760 0.66 9/20
SCHEMBL446729 SCHEMBL446729 0.50 8/20
SCHEMBL446730 SCHEMBL446730 0.50 8/20
SCHEMBL336390 SCHEMBL336390 0.57 7/20
SCHEMBL336770 SCHEMBL336770 0.55 6/20
SCHEMBL413932 SCHEMBL413932 0.54 6/20
SCHEMBL443148 SCHEMBL443148 0.54 6/20
SCHEMBL336266 SCHEMBL336266 0.56 5/20
SCHEMBL442089 SCHEMBL442089 0.46 4/20
SCHEMBL135776 SCHEMBL135776 1.00 3/20
SCHEMBL138388 SCHEMBL138388 1.00 3/20
SCHEMBL137228 SCHEMBL137228 0.90 3/20
SCHEMBL138631 SCHEMBL138631 0.88 3/20
SCHEMBL138867 SCHEMBL138867 0.85 3/20
SCHEMBL138628 SCHEMBL138628 0.85 3/20
SCHEMBL481136 SCHEMBL481136 0.85 3/20
SCHEMBL137103 SCHEMBL137103 0.84 3/20
SCHEMBL138732 SCHEMBL138732 0.83 3/20

Clinical trials — most relevant to MAPKAP1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Doxycycline In Lymphangioleiomyomatosis (LAM) PHASE4COMPLETED
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer PHASE2COMPLETED
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma PHASE1/PHASE2COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer PHASE2COMPLETED
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC PHASE2COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy PHASE1UNKNOWN
Rapalog Pharmacology (RAP PAC) Study PHASE1RECRUITING
Glutamine Supplementation in People With Immune Dysregulation EARLY_PHASE1WITHDRAWN
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry) nanRECRUITING
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
RASopathy Biorepository nanRECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial nanRECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Rapamycin as a Means of Interference With Reconsolidation of Posttraumatic Stress Disorder-related Traumatic Memory nanCOMPLETED
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAPKAP1 binder may also engage these)

ProteinNameSimilarity
Q6QD73 — 1.000 Q6QD73 →
Q5RDV5 — 1.000 Q5RDV5 →
A2VDU2 — 1.000 A2VDU2 →
Q6AYF1 — 1.000 Q6AYF1 →
Q8BKH7 — 1.000 Q8BKH7 →
Q9W6S3 — 1.000 Q9W6S3 →
Q7ZYH1 — 1.000 Q7ZYH1 →
A4IIM3 — 1.000 A4IIM3 →
Q8CIB5 — 0.980 Q8CIB5 →
Q8N960 — 0.979 Q8N960 →
P59113 — 0.978 P59113 →
Q5RID7 — 0.978 Q5RID7 →
A0JN62 — 0.978 A0JN62 →
Q5R8M5 — 0.978 Q5R8M5 →
Q9BQL6 — 0.977 Q9BQL6 →
F1Q8X5 — 0.976 F1Q8X5 →
Q6DRP4 — 0.975 Q6DRP4 →
Q9Y2L5 — 0.975 Q9Y2L5 →
P48553 — 0.974 P48553 →
Q7TSG1 — 0.974 Q7TSG1 →
Q8QFR2 — 0.974 Q8QFR2 →
Q8TAP6 — 0.974 Q8TAP6 →
Q28C34 — 0.974 Q28C34 →
Q8BIK4 — 0.974 Q8BIK4 →
Q15036 — 0.973 Q15036 →
Q8IZC4 — 0.973 Q8IZC4 →
Q6DG43 — 0.973 Q6DG43 →
Q5RCP7 — 0.973 Q5RCP7 →
Q8N6S4 — 0.972 Q8N6S4 →
Q6NRD0 — 0.972 Q6NRD0 →